Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Trial Profile

Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromfenac (Primary)
  • Indications Ocular inflammation; Ocular pain; Postoperative pain
  • Focus Therapeutic Use
  • Sponsors ISTA Pharmaceuticals
  • Most Recent Events

    • 17 Aug 2011 New trial record
    • 14 Jul 2011 Results of a pooled analysis of two identically-designed studies (204785 and 204793) published in the Current Medical Research and Opinion.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top